Hot Features
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosph... Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.79 | -10.0893997446 | 7.83 | 7.84 | 6.65 | 864236 | 7.03357719 | CS |
| 4 | -0.91 | -11.4465408805 | 7.95 | 8.74 | 6.65 | 762867 | 7.47189961 | CS |
| 12 | 0.01 | 0.142247510669 | 7.03 | 8.74 | 6.045 | 608985 | 7.27447911 | CS |
| 26 | 0.5 | 7.64525993884 | 6.54 | 8.74 | 5.35 | 550987 | 6.86797729 | CS |
| 52 | 6.2668 | 810.501810657 | 0.7732 | 8.74 | 0.47 | 987920 | 3.54385376 | CS |
| 156 | 5.49 | 354.193548387 | 1.55 | 8.74 | 0.202 | 939298 | 1.62435653 | CS |
| 260 | -1.51 | -17.6608187135 | 8.55 | 8.74 | 0.202 | 1039654 | 1.74269912 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.